The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
COVID-19 Vaccine Development for LMICs
Pfizer Global Medical Grants (GMG) and BioNTech support the global healthcare community’s independent research initiatives to improve patient outcomes in areas of unmet medical need that are aligned with our medical and/or scientific strategies. The competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal review process to make final grant decisions. Organizations may submit an application addressing the research areas as outlined in the specific RFP.
The intent of this RFP is to support COVID-19 vaccine development for LMICs. The support provided by Pfizer will be through the provision of the Pfizer-BioNTech COVID-19 Vaccine for comparator studies. No funding will be provided.
We are particularly interested in supporting research in the following areas:
• Clinical studies designed to lead to approval and availability of new COVID-19 vaccine(s)
• Such vaccine(s) must be intended to protect large populations in LMIC, based on study design, GMP manufacturing capacity, product characteristics, the applicant’s ability to manage timely GCP-compliant clinical trials and regulatory filings and other relevant factors
Grant applications may be submitted throughout the year and application reviews and decisions will be completed on a rolling basis.
RFP end date: December 31, 2022
Geographic Scope: Global, with preference given to organizations with a presence in a low- and middle-income country (LMIC)*
*Requests from China, Hong Kong, Macau, and Taiwan are ineligible as these markets are outside the Pfizer/BioNTech collaboration
• The institution and principal investigator (PI) must be based in one of the eligible countries noted above. • Only organizations are eligible to receive grants, not individuals or medical practice groups. • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work. • Applicant must be affiliated with a host institution • Requests from China, Hong Kong, Macau, and Taiwan are ineligible as these markets are outside the Pfizer/BioNTech collaboration